CBD and Anxiety in 2015: Promising Signals, Mostly From Single Doses | Research

The takeaway

This narrative review found CBD linked to reduced anxiety in acute tests, but evidence for multi-week treatment in diagnosed patients was scarce.

Readers weighing the early CBD-for-anxiety story against what had actually been tested in people by 2015.

5
anxiety disorders had preclinical support under acute CBD dosing, but human long-term data were scarce.

What the researchers found

Across animal models, CBD showed consistent anxiolytic-like effects spanning generalized anxiety, panic, social anxiety, obsessive-compulsive disorder, and post-traumatic stress. That is the strongest part of the evidence base, but it is preclinical.

Human data pointed in the same direction, with CBD associated with lower anxiety in acute experimental settings. Most of these were single-dose studies, often in tasks designed to provoke anxiety, and only a few included people with diagnosed anxiety disorders. Evidence on repeated or chronic dosing, real-world functioning, and sustained symptom change was largely missing at the time of publication.

Why it matters

By 2015, public interest in CBD for anxiety outpaced clinical evidence. This review pulled the scattered studies into one place and clarified a gap: encouraging acute signals with very limited data on sustained use in people with diagnosed anxiety disorders.

The numbers in context

- Publication year: 2015, narrative review of preclinical, human experimental, clinical, and epidemiological studies

- Anxiety conditions covered: 5 named disorders (GAD, panic disorder, social anxiety disorder, OCD, PTSD)

- Human evidence: largely acute, single-dose studies in anxiety-provoking tasks; few trials in clinical populations

- Chronic dosing: very limited investigation of multi-week or maintenance use

How the study worked

The authors reviewed preclinical experiments, human laboratory studies, early clinical reports, and epidemiological findings on CBD and anxiety. It reads as a narrative synthesis rather than a formal systematic review. Study designs, doses, and populations varied widely, and the abstract does not report a risk-of-bias assessment or meta-analysis. The strongest human data involved acute dosing in experimental paradigms, not long-term treatment trials.

Who was studied

Review of preclinical, human experimental, clinical, and epidemiological studies; Country not specified.

What this study cannot tell us

Narrative review without reported risk-of-bias grading or quantitative synthesis. Heavy reliance on preclinical work and acute human experiments. Few studies in patients with diagnosed anxiety disorders. Minimal data on repeated or chronic dosing, dose-response, or functional outcomes. Funding and conflicts not reported in the abstract.

How to read the evidence

Rated preliminary: narrative review with encouraging preclinical and acute human findings, but few clinical trials in diagnosed patients and minimal chronic dosing data.

When this study was published

Published in 2015, before the surge of over-the-counter CBD products and newer clinical studies. Later research expanded the dataset but variability in products, doses, and outcomes still complicates interpretation.

The bigger picture

CBD is often discussed as an anxiolytic, and this review is one reason why. It lined up consistent preclinical findings with early human signals under acute dosing. The translation problem remains: animal models are not the same as people with chronic anxiety, and single-dose lab tasks do not establish whether multi-week CBD use changes day-to-day symptoms, sleep, or functioning. Without standardized products, dosing ranges, or long-term outcomes, the 2015 evidence base supported potential rather than established therapeutic effects.

Replication

Not stated in abstract.

Funding

Not reported in abstract.

Conflicts of interest

Not reported in abstract.

Questions still open

Do multi-week CBD regimens sustain anxiety reductions beyond single-dose effects?
Which doses, formulations, and routes of administration are associated with the strongest and most consistent anxiolytic signals?
How do results differ between healthy volunteers in lab tasks and patients with diagnosed anxiety disorders?
What are the effects of chronic CBD use on sleep, avoidance behavior, and quality of life in anxiety disorders?
How do product variability and concomitant medications influence outcomes?

Common questions

Did the review find that CBD reduces anxiety in humans?

It found human studies where acute CBD dosing was associated with lower anxiety during lab tasks. However, trials in diagnosed patients were few and long-term outcomes were largely untested.

Which anxiety disorders were covered?

Preclinical evidence addressed generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive-compulsive disorder, and post-traumatic stress disorder. Human studies focused mostly on acute anxiety responses, with limited work in diagnosed clinical groups.

Was long-term CBD use studied?

Hardly at all in 2015. The review notes limited investigation of repeated or chronic dosing and few data on sustained symptom change.

Was this a systematic review with a meta-analysis?

No. The abstract describes a narrative assessment without reported risk-of-bias grading or pooled effect sizes.

Read the original research

Cannabidiol as a potential treatment for anxiety disorders

Neurotherapeutics, 12(4), 825-836

Neurotherapeutics is a reputable journal focusing on the intersection of neurology and therapeutics, known for publishing high-quality research.

View on PubMed ↗

Citation

Blessing, Esther M.; Steenkamp, Maria M.; Manzanares, Jorge; Marmar, Charles R.. (2015). Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics, 12(4), 825-836.